Rising prevalence of cancer and increasing adoption of personalized medicine to drive the growth of global neoantigen cancer vaccine market.
According to TechSci Research report, “Global Neoantigen Cancer Vaccine Market By Product (Personalized neoantigen vaccine, Off-the shelf neoantigen vaccine), By Neoantigen Type (Synthetic long peptide (SLP), Nucleic Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (RNA sequencing, Whole genome sequencing, HLA typing), By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun, Others), By Application (Lung, Melanoma, Gastrointestinal, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities, 2026”, global neoantigen cancer vaccine market is expected to reach USD1754.44 million in 2026, growing with double-digit CAGR of 54.18% during the forecast period. Neoantigen cancer vaccines are the type of vaccines that help to boost the immune system with the help of single or several antigens.
Surging prevalence of cancer is one of the major factors accounting for the growth of global neoantigen cancer vaccines market. Moreover, rapid adoption of personalized medicines for the patient’s treatment on individual level is further expected to aid in the growth of global neoantigen cancer vaccine market through the forecast period. The product type is segmented into personalized neoantigen vaccine and off-the shelf neoantigen vaccine. The personalized neoantigen vaccines is expected to dominate the market in the forecast period due to high number of clinical trials and extensive R&D for the development of personalized neoantigen cancer vaccines.
In addition to this, continuous advancements in several drug delivery technologies is anticipated to positively influence the growth of the global neoantigen cancer vaccine market in the years to come. Also, increased funding for executing research and development activities is making headway for the growth of global neoantigen cancer vaccines market across the globe. Along with this, expected launch of first neoantigen vaccine Tedopi in the market, is estimated to boost the market growth through 2026. However, high cost of personalized cancer vaccines as well as obstacles in clinical development are the major factors that might restrain the growth of the global neoantigen cancer vaccines market through 2026.
Browse 3 market data Tables and 223 Figures spread through 284 Pages and an in-depth TOC on “Global Neoantigen Cancer Vaccine Market”
Global neoantigen cancer vaccine market can be segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company, and region. Considering the delivery mechanism, the market is fragmented into liposomes, virosomes electroporation, gene gun, and others. The liposomes segment is anticipated to grow at the high rate during the forecast period. In terms of technology, the market is fragmented into RNA sequencing, whole genome sequencing, and HLA typing. Out of which, RNA sequencing technology segment is forecast to register high growth in the next 5 years on account of studying what genes are mis regulated.
OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG among others are the leading players operating in global neoantigen cancer vaccines market. The leading players are adopting several growth strategies to enhance the market scenario of neoantigen cancer vaccines. Some of the competitive strategies include partnerships, collaborations, business expansions, as well as mergers and acquisitions, partnership opportunities in order to diverse their product portfolio and to strengthen their market position.
Download sample report @ https://www.techsciresearch.com/sample-report.aspx?cid=4566
Customers can also request for 10% free customization on this report.
“North America is forecast to dominate the global neoantigen cancer vaccine market with a highest market share among all the regions during the next five years on the account of the existence of many key market players in this region. Asia-Pacific is anticipated to register high growth during the forecast period which can be accredited to rising population that has cancer and significant number of clinical trials going on in China. Furthermore, mounting investment in research activities and improvement in healthcare technologies is expected to aid the growth of neoantigen cancer vaccines market in the region until 2026.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Neoantigen Cancer Vaccine Market By Product (Personalized neoantigen vaccine, Off-the shelf neoantigen vaccine), By Neoantigen Type (Synthetic long peptide (SLP), Nucleic Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (RNA sequencing, Whole genome sequencing, HLA typing), By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun, Others), By Application (Lung, Melanoma, Gastrointestinal, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities, 2026” has evaluated the future growth potential of global neoantigen cancer vaccines market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global neoantigen cancer vaccines market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017